Stifel Maintains Buy on Blueprint Medicines, Raises Price Target to $97-Report Released on 8 January 2024
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino has reaffirmed a Buy rating on Blueprint Medicines (NASDAQ:BPMC) and increased the price target from $95 to $97, as reported on January 8, 2024.
January 09, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Bradley Canino maintains a Buy rating on Blueprint Medicines and raises the price target from $95 to $97.
The increase in price target by Stifel reflects a positive outlook on Blueprint Medicines, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100